We are thrilled to announce that Qualiphy is now offering screening for Semaglutide, the active ingredient in Wegovy, Ozempic and Rybelsus & Tizepatide, the active ingredient in Zepbound and Mounjaro
The Procedure Process:
For patients embarking on their weight loss journey with Semaglutide and Tirzepatide, here’s our comprehensive and safe approach:
Initial Screening for Weight Loss:
- For first-time patients, select the “Weight Loss Initial Consult (Semaglutide/Tirzepatide)” exam
- This exam requires recent lab work included to ensure patient safety and suitability for the treatment.
- During this screening, patients will receive education on necessary lifestyle changes and how to maximize the benefits of the treatment.
- Initial dosages are conservative to gauge patient response: 0.25mg for Semaglutide and 2.5mg for Tirzepatide.
Follow-Up Dosages:
- Monthly follow-ups are required to monitor progress and adjust dosages.
- Dosage increases are patient-dependent and based on health and preference.
- Semaglutide: Increases monthly, starting from 0.5mg to a dose of 2.4mg.
- Tirzepatide: Gradual increase from 5mg to a dose of 15mg.
Pricing:
- The initial exam, including lab work review, is priced at $37.99.
- Each subsequent follow-up evaluation is $27.99 and does not require new lab work.
Patient-Centric Approach:
- We empower patients to make informed decisions about their dosage increases, with the option to remain on a lower dose if they prefer.
- Our team of providers is dedicated to ensuring a safe, effective, and personalized weight loss journey for every patient.
- We adhere to a strict safety protocol, including not clearing anyone with a BMI less than 25% for the initial dose.
By introducing Semaglutide and Tirzepatide in our treatment options, Qualiphy is committed to offering advanced, effective solutions for weight management. We look forward to supporting our patients in achieving their health and wellness goals.
About Semaglutide and Tirzepatide:
Semaglutide is a GLP-1 receptor agonist, primarily used to improve blood sugar control in adults with type 2 diabetes. Recently, it has gained attention for its effectiveness in weight loss by reducing appetite and food intake.
Tirzepatide, on the other hand, is a dual GIP and GLP-1 receptor agonist. It not only aids in blood sugar control but also significantly promotes weight loss. The dual mechanism of Tirzepatide offers a broader approach in managing weight, potentially leading to more significant weight loss outcomes compared to medications that act on a single pathway.
